Primitive neuroectodermal tumor
MONDO:0005462A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.
Also known as: PNET, neuroectodermal neoplasm, neuroectodermal tumor, neuroectodermal tumour, primitive neuroectodermal neoplasm, primitive neuroectodermal tumor, primitive neuroectodermal tumor (PNET), primitive neuroectodermal tumour (PNET)
1645 clinical trials for this condition and its sub-types, 14 tagged with Primitive neuroectodermal tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Primitive neuroectodermal tumor
-
Neuroblastic tumor 3 trials · 206 incl. sub-types
3 sub-types
- Neuroblastoma 198 trials · 204 incl. sub-types Sub-types →
- Ganglioneuroblastoma 20 trials · 21 incl. sub-types Sub-types →
- Ganglioneuroma 5 trials Sub-types →
-
Central nervous system primitive neuroectodermal neoplasm 8 trials · 24 incl. sub-types
8 sub-types
- Intracranial primitive neuroectodermal tumor 0 trials · 8 incl. sub-types Sub-types →
- Childhood central nervous system primitive neuroectodermal neoplasm 6 trials Sub-types →
- Ependymoblastoma 5 trials Sub-types →
- Ganglioneuroma 5 trials Sub-types →
- Central nervous system tumor with bcor internal tandem duplication 1 trial
- Adult central nervous system primitive neuroectodermal neoplasm 0 trials Sub-types →
- Spinal cord neuroblastoma 0 trials
- Spinal cord primitive neuroectodermal tumor 0 trials
-
Peripheral primitive neuroectodermal tumor 7 trials · 8 incl. sub-types
3 sub-types
-
Melanotic neuroectodermal tumor 0 trials
Most studied deeper sub-types
-
Can a targeted pill slow brain tumor growth after surgery?
Disease control ApprovedThis expanded access program offers vorasidenib, an oral drug, to people aged 12 and older with IDH-mutated glioma who have had surgery. The drug targets specific genetic mutations in tumor cells. The goal is to see if it can help control the disease without immediate need for ra…
Sponsor: Servier • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Engineered immune cells injected directly into brain show promise for kids with deadly tumors
Disease control OngoingThis early-phase study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The therapy a…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC